An increasing number of novel drugs, including cyclin-dependent kinase 4/6 inhibitors, poly ADP-ribose polymerase inhibitors, and programmed death-ligand 1 inhibitors, have been shown to improve outcomes and have been recently approved for breast cancer treatment in the past few years (32). This evidence concerns the gene CDK4 and breast cancer.